Is There a Difference in Occurrence of Complications Between Adults With Hemoglobin SS and Hemoglobin SC Disease: An Extended Systematic Review Authors: Martijn van der Meer, Kim Velsink, Wing H. Tong, Jan W. Schoones Published: 2026 ABSTRACT ABSTRACTSickle cell disease (SCD) is characterized by both acute and chronic complications. The clinical manifestation of these complications differs between genotypes. Given the large amount of research already published, this systematic review aims to offer a complete overview of types of sickle cell complications between adults in the most common genotypes Hemoglobin SS (HbSS) and Hemoglobin SC (HbSC), putting options for further research into perspective. An extensive literature search was performed to study all available evidence on these complications. This review was performed according to the “Preferred Reporting Items for Systematic Reviews and Meta‐Analyses” (PRISMA) statement guidelines, and was performed on January 2, 2024. A total of 710 references were identified. After careful screening, 521 records were excluded based on title and abstract and other exclusion criteria. In total, 158 articles were excluded after full‐text assessment. Our analysis of 31 studies highlights key differences in complications between HbSS and HbSC genotypes in sickle cell disease (SCD). Vaso‐occlusive crises (VOCs) remain the most common acute complication in both genotypes. HbSS patients experience more frequent VOCs, while HbSC patients generally have a milder clinical course when it comes to acute complications. Chronic complications, particularly in the ocular and pulmonary systems, are more prevalent in HbSC patients. However, as acute complications are more common in HbSS and chronic complications more common in HbSC, both genotypes face progressive organ damage due to recurrent ischemic injury and inflammation. Abbreviations acute chest syndrome cerebrovascular accident epiretinal membrane hemoglobin SC hemoglobin SS low‐ and middle‐income countries proliferative sickle retinopathy sickle cell anemia sickle cell disease sickle cell maculopathy Sub‐Saharan Africa vaso‐occlusive crisis Introduction Worldwide, each year many newborns are affected by sickle cell disease (SCD). It was found that the estimated number of cases will increase from 305 800 in 2010 to 404 200 in 2050 [1]. Likewise, it was also projected that the number of affected newborns will increase by 30% by 2050, with the majority of this increase occurring in Sub‐Saharan Africa (SSA) [1]. In the Netherlands, it was estimated that between 2500 and 3000 patients have been diagnosed with SCD, half of whom are pediatric offspring. Of note, one‐third of these new pediatric cases with SCD are immigrants; they may not benefit from neonatal screening [2]. SCD is an autosomal recessive inherited disease [3] caused by a variation in the hemoglobin subunit beta (HBB) [4]. More specific, HbS and HbC are different variants that combine to produce the SCD genotypes HbSS or HbSC [3]. In the end, red blood cells (RBCs) may become stiff and take on a crescent or “sickle” shape when they lose oxygen [5]. The most common type of sickle cell disease (SCD) is hemoglobin SS disease (HbSS), also known as sickle cell anemia (SCA), accounting for the majority of all SCD cases, namely 60%–70% [3]. Another type, hemoglobin SC disease (HbSC), is generally considered as a milder form, associated with fewer severe complications and representing about 25%–30% of SCD cases [3]. SCD includes both sickle beta thalassemia 0 and SS genotype. The total percentage provided for SCD and HBSC may not be completely correct. As it depends on the geography as there are many genotypes globally which collectively should make 100% [3]. It was found that the difference in oxygenscan variables and blood viscosity between HbSS and HbSC individuals could clarify the different presentation of their clinical and hematological features [6]. These authors suggested that the effects of various drugs in HbSC patients should account for the specific determinants of RBC rheology and sickling in HbSC. Furthermore, the pathophysiology is complex and involves several factors, for example impaired vascular reactivity, inflammation, oxidative stress, abnormal vascular adhesion and coagulation, and altered blood rheology [7]. The aforementioned numbers of HbSS and HbSC cases can vary depending on geographical regions. HbSC is more common in regions with populations genetically descended from West African and Caribbean communities [1]. HbSS, on the other hand, is widespread across tropical and subtropical regions, including SSA, South Asia, the Middle East, and the Mediterranean. In these regions, genetic variants of hemoglobin, such as HbS, provide an evolutionary advantage against malaria, which has increased their prevalence within these populations [8]. SCD is a chronic condition characterized by vaso‐occlusion, which can lead to a wide range of acute and chronic complications. Acute complications include vaso‐occlusive crises, acute chest syndrome, and stroke, while chronic complications include retinopathy, nephropathy, and cardiovascular disease [9]. Together, these and numerous other complications contribute to a substantial reduction in both quality of life and life expectancy among affected individuals [8]. More specifically, there are biological and vascular differences between HbSS and HbSC. A recent paper compared the oxygenscan variables between HbSS and HbSC, with or without hydroxyurea (HU) [6]. Connes et al. [6] found that RBC deformability was lower in HbSS patients without HU compared to HbSS patients with HU and HbSC patients with or without HU. And these authors also detected that the ability of RBC to recover their maximum deformability after a deoxygenation/reoxygenation cycle was lower in HbSC compared to HbSS patients. To add, a recent scoping review discussed the role of systematic metabolomic profiling [10]. The Dutch authors identified associations with hemolysis, vaso‐occlusive events, nephropathy, tricuspid regurgitant jet velocity, and mortality. Likewise, new research and also new therapy are currently being conducted and these have been published [11, 12]. This systematic review aims to provide an overview of complications associated with SCD in adults with HbSS and HbSC genotypes and to identify areas for further research. Methods The objective of this extensive literature search was to identify all available evidence on complications in HbSS and HbSC disease. This review was performed according to the “Preferred Reporting Items for Systematic Reviews and Meta‐Analyses” (PRISMA) statement guidelines [13]. Search Strategy and Selection Procedure In cooperation with a trained information specialist (J.W.S.), a detailed search strategy was composed. The query consisted of the combination of the following four concepts: Sickle cell anemia.Hemoglobin SS and SC.Complications/prognosis/outcome.Adult. Sickle cell anemia. Sickle cell anemia. Hemoglobin SS and SC. Hemoglobin SS and SC. Complications/prognosis/outcome. Complications/prognosis/outcome. Adult. Adult. For these concepts, all relevant keyword variations were used, not only keyword variations in the controlled vocabularies of the various databases, but the free text word variations of these concepts as well. The search strategy was optimized for all consulted databases, taking into account the differences of the various controlled vocabularies as well as the differences of database‐specific technical variations (e.g., the use of quotation marks). The following databases were searched: PubMed, Embase (OVID), Web of Science (Core Collection), Cochrane Library (incl. CENTRAL), Emcare (OVID), and Academic Search Premier (EBSCOhost). All details of the search strategy can be found in the Supporting Information. In total, 710 references were identified. The search was performed on January 2, 2024. All identified studies were screened by two independent reviewers (M.M., K.V.) for eligibility based on the inclusion‐ and exclusion criteria. This screening was performed in Rayyan in the following order: title & abstract; and full text articles [14]. Any discrepancies in the article selection were resolved through discussion, when necessary, with a third reviewer (W.H.T.). The following inclusion criteria applied in the study selection process: Studies reporting the prevalence of HbSS and HbSC complications.Studies involving patients with a mean/median (depending on what was used in the respective study) age > 20 years old. This was done to minimize the potential influence of data about children on the study results. Studies could be included if (1) the results were split by age, (2) when children grew into adults during the follow‐up, and (3) if the follow‐up was long enough for complications to occur.Studies of the following study type: cross‐sectional, prospective cohort, retrospective cohort, longitudinal cohort, and clinical trials. Studies reporting the prevalence of HbSS and HbSC complications. Studies reporting the prevalence of HbSS and HbSC complications. Studies involving patients with a mean/median (depending on what was used in the respective study) age > 20 years old. This was done to minimize the potential influence of data about children on the study results. Studies could be included if (1) the results were split by age, (2) when children grew into adults during the follow‐up, and (3) if the follow‐up was long enough for complications to occur. Studies involving patients with a mean/median (depending on what was used in the respective study) age > 20 years old. This was done to minimize the potential influence of data about children on the study results. Studies could be included if (1) the results were split by age, (2) when children grew into adults during the follow‐up, and (3) if the follow‐up was long enough for complications to occur. Studies of the following study type: cross‐sectional, prospective cohort, retrospective cohort, longitudinal cohort, and clinical trials. Studies of the following study type: cross‐sectional, prospective cohort, retrospective cohort, longitudinal cohort, and clinical trials. The following exclusion criteria were applied in the study selection process: Studies including pregnant women.Studies involving only patients under 18 years of age.Studies focused on therapies for hemoglobin SS or hemoglobin SC disease.Studies without any comparison between HbSS and HbSC disease.(Systematic) reviews, case reports, case series, and animal‐only studies.Studies published solely in languages other than English or Dutch. Studies including pregnant women. Studies including pregnant women. Studies involving only patients under 18 years of age. Studies involving only patients under 18 years of age. Studies focused on therapies for hemoglobin SS or hemoglobin SC disease. Studies focused on therapies for hemoglobin SS or hemoglobin SC disease. Studies without any comparison between HbSS and HbSC disease. Studies without any comparison between HbSS and HbSC disease. (Systematic) reviews, case reports, case series, and animal‐only studies. (Systematic) reviews, case reports, case series, and animal‐only studies. Studies published solely in languages other than English or Dutch. Studies published solely in languages other than English or Dutch. When two or more eligible studies reported on the same dataset, both were included if they individually presented original outcomes. If this was not the case, the methodologically most appropriate one was selected for final analysis. Data Extraction The study characteristics collected from the selected articles included general data (authors, year of publication, study type, sample size), participants' characteristics (age, sex, diagnosis), and the occurrence of complications in HbSS and HbSC disease. If in a study the results of children and adults were separated, we only used the results of the adults. If the results of children and adults were put together, we used these results when articles met the aforementioned inclusion criteria regarding children in the study. Eventually, we compared the occurrence of specific complications in HbSC disease with the occurrence in HbSS disease. Quality Assessment The methodological quality of all included studies was systematically assessed by two independent reviewers (M.M., K.V.) using the Quality in Prognosis Studies (QUIPS) tool [15, 16]. Conflicts or doubts were resolved through discussion, if necessary, with a third reviewer (WHT). The QUIPS tool rates the risk of bias (ROB) in six domains: study participation, study attrition, measurement of prognostic factors, outcome measurement, study confounding, and statistical analysis and reporting. These domains were rated as either high (+), moderate (+/−) or low (−) risk of bias. In cases of uncertainty or when valid arguments existed for two possible ratings (e.g., low/moderate or moderate/high), the highest potential risk of bias was assigned to the domain as a precautionary measure. Importantly, this quality assessment was not used as additional exclusion or inclusion criteria. Results A total of 710 references were identified. After careful screening, 521 records were excluded based on title and abstract and other exclusion criteria. In total, 158 articles were excluded after full‐text assessment. Finally, 31 articles were included (Figure 1). No additional articles were used from the reference lists of the selected records. Flow diagram of the complete study selection process. In the Supporting Information, additional information among the process may be found. Study Characteristics Table 1a shows the following characteristics of each study: study design, number of patients with male/female ratio, the participants' age, diagnosis and complications investigated in the concerning study. Of the 31 selected studies, 10 cohorts were from cross‐sectional studies, and the remaining from observational cohort studies (16 prospective in design and there were five retrospective studies). The studies included in this review were conducted between 1972 and 2023. Two articles authored by the same researcher were identified [17, 18]. These studies analyzed data derived from largely overlapping cohorts. It was found that in most studies the proportion of HbSS patients was larger than that of HbSC patients. This was due to a higher total prevalence of HbSS in the general population. Additionally, in two studies, the numbers of HbSS and HbSC patients were equal. Finally, seven studies indicated a higher ratio of HbSC patients compared to HbSS patients [9, 19]. TABLE 1aThis table consists of complete information regarding the respective authors with the year of publication, the study design, the number of participants including gender, the age (in years) of all participants, the diagnosis of SCD, and finally the studied complications.DomainsStudy participationStudy attritionPrognostic factor measurementOutcome measurementStudy confoundingStatistical analysis and reportingAcheson et al. 1986+/−−−+/−++AlRyalat et al. 2021−−−−−−Ballas et al. 1982+/−+/−−−++/−Beral et al. 2019−−−−+/−−Bortolotti et al. 2020−−−−−−Castro et al. 1994+/−+/−−+/−−−Clarkson 1992−−−−+/−+/−Colella et al. 2015−−−−−−Condon et al. 1972−−−−+/−−Condon et al. 1980+/−−−+/−++/−Crawford et al. 1991−−−−+/−+/−David et al. 1993+/−+−+/−++/−Downes et al. 2005−−−−−−Drawz et al. 2016−+/−−−+/−−Ephraim et al. 2015−−−−−−Fowler et al. 1991+/−−−−−−Fox et al. 1990+/−−−−++/−Ghunney et al. 2023+/−−−−−−Guedeney et al. 2018−−−−−+/−Hill et al. 1975+−+/−−++Jonavic et al. 2006+/−+/−−−−+/−Klings et al. 2008−−−−+/−−Leveziel et al. 2011−−−+/−−−Lins et al. 2021−−−−−−Meurs et al. 1990−−−−+/−+/−Meurs et al. 1991−−−−+/−−Milner et al. 1993−−−−−−Moreira et al. 2006+/−−−+/−++Moriarty et al. 1987+/−−+/−−+/−+/−Olaniyi et al. 2007+/−+−+/−++/−Sahak et al. 2020−−−−−+/− This table consists of complete information regarding the respective authors with the year of publication, the study design, the number of participants including gender, the age (in years) of all participants, the diagnosis of SCD, and finally the studied complications. Quality Assessment A detailed summary of the individual study assessments is provided in the Supporting Information. Overall, the results show that several studies followed strict methodological standards. However, a considerable number had moderate to high risks of bias, particularly in the areas of study confounding and statistical analysis and reporting (Table 1b). TABLE 1bStudy characteristics.Authors and year of publicationStudy designNumber of participants (male/female)Participants' age in years a Diagnosis (HbSS/HbSC) b Complication(s) studied1Acheson et al. 1986Prospective cohort study414 (191/223)—182/232Iris atrophy2AlRyalat et al. 2021Cross‐sectional study1867 (830/1037)27.7 (mean)971/378PSR3Ballas et al. 1982Prospective cohort study93 (37/56)—66/27VOC, CVA, thromboembolic complications, priapism, splenomegaly, retinopathy, cholelithiasis, hepatomegaly, renal papillary necrosis, infections (in general), leg ulcers, osteomyelitis4Beral et al. 2019Prospective cohort study70 (28/42)40.3 (mean)37/33SCM, retinopathy, leg ulcers, osteonecrosis, nephropathy, ACS, VOC5Bortolotti et al. 2020Cross‐sectional study68 (33/35)42.5 (mean)17/13Splenomegaly, cholelithiasis6Castro et al. 1994Prospective cohort study3751 (−)—2534/845ACS7Clarkson 1992Prospective cohort study150 (73/77)22.0 (median)109/29Retinopathy, iris atrophy, epiretinale membrane8Colella et al. 2015Cross‐sectional study122 (−)38 (median)39/56ACS, stroke, leg ulcers, retinopathy, osteonecrosis, pulmonary hypertension, autosplenectomy9Condon et al. 1972Retrospective cohort study70 (31/39)—76/70Retinopathy10Condon et al. 1980Prospective cohort study313 (−)30.1 (mean)115/157PSR11Crawford et al. 1991Cross‐sectional study75 (33/42)31.0 (mean)50/13Hearing loss12David et al. 1993Prospective cohort study138 (64/74)26.3 (mean)81/42AVN of the humeral head13Downes et al. 2005Prospective cohort study473 (240/233)23.8 (median)307/166PSR14Drawz et al. 2016Prospective cohort study590 (273/317)38.7 (mean)463/127Microalbuminuria, macroalbuminuria, proteinuria15Ephraim et al. 2015Cross‐sectional study194 (84/110)23.3 (mean)142/52CKD, albuminuria16Fowler et al. 1991Cross‐sectional study84 (84/0)31.8 (mean)52/10Priapism17Fox et al. 1990Prospective cohort study1319 (574/745)—786/533PSR18Ghunney et al. 2023Retrospective cohort study1278 (774/774)30.9 (mean)639/639VOC, ACS, Severe symptomatic chronic anemia, AVN, stroke, priapism, nefropathy, PSR, chronic leg ulcer, systemic hypertension, chronic pain19Guedeney et al. 2018Retrospective cohort study120 (50/70)31.0 (median)60/60Cardiac involvement20Hill et al. 1975Retrospective cohort study400 (−)35 (mean)225/35Epiphyseal changes21Jonavic et al. 2006Prospective cohort study119 (−)32.4 (mean)39/40Hearing loss22Klings et al. 2008Prospective cohort study124 (32/92)31.9 (mean)97/27PAH, left‐sided heart disease23Leveziel et al. 2011Retrospective longitudinal cohort study942 (391/551)31.0 (median)629/313Retinopathy, cardiac involvement, pulmonary involvement, osteonecrosis (in general), ACS, deafness/tinnitus, CVA, renal involvement, systemic infection, acute pyelonephritis, osteomyelitis, priapism24Lins et al. 2021Cross‐sectional study96 (30/66)34.3 (mean)26/22AVN of the femoral head, bone infarct, bone marrow necrosis25Meurs et al. 1990Cross‐sectional study180 (80/100)29.0 (mean)81/97PSR, severe vision loss, bilateral blindness26Meurs et al. 1991Cross‐sectional study178 (−)29.0 (mean)81/97Retinopathy, iris atrophy27Milner et al. 1993Prospective cohort study2524 (−)—1737/510AVN of the humeral head28Moreira et al. 2006Cross‐sectional study53 (21/32)33.3 (median)29/24Stroke, AVN, retinopathy, ACS29Moriarty et al. 1987Prospective longitudinal cohort study355 (164/191)—132/223Epiretinal membrane30Olaniyi et al. 2007Prospective cohort study220 (95/125)24.7 (mean)193/27Hepatomegaly, splenomegaly31Sahak et al. 2020Prospective cohort study74 (36/38)37.0 (median)42/24SCM Note: This table shows the overview of the ROB of SCD. In the Supporting Information, additional information among the process may be found. When data on a specific characteristic in a study could not be found, such as the male/female ratio or the participants' mean or median age, it is indicated with a minus sign (−). a Mean or median age. b If the sum of these numbers does not match the total number of participants, the difference between these two numbers are participants with a different type of SCD (which we did not investigate in this study). Study characteristics. Note: This table shows the overview of the ROB of SCD. In the Supporting Information, additional information among the process may be found. When data on a specific characteristic in a study could not be found, such as the male/female ratio or the participants' mean or median age, it is indicated with a minus sign (−). Mean or median age. If the sum of these numbers does not match the total number of participants, the difference between these two numbers are participants with a different type of SCD (which we did not investigate in this study). Analysis of Complications in Sickle Cell Disease The results have been divided into acute and chronic complications for a clear overview. For each complication in Tables 2 and 3, the mean prevalence (in %) of complications was calculated by averaging all the percentages from the studies used for a specific complication. Additionally, the total number of patients was calculated by summing the total number of patients in either HbSS or HbSC disease in each study. TABLE 2Prevalence of acute complications in HbSS and HbSC genotypes in SCD.% of HbSS patients with eventTotal amount of HbSS patients (n)% of HbSC patients with eventTotal amount of HbSC patients (n)Studies usedPainfull sickle crisis/VOC a 46.774228.5699Ballas (1982), Beral (2019), Ghunney (2023)Acute chest syndrome (ACS) b 19.14089.1228Beral (2019), Castro (1994), Colella (2015), Ghunney (2023), Leveziel (2011), Moreira (2006)Priapism c 25.95885.4398Ballas (1982), Fowler (2018), Ghunney (2023), Leveziel (2011)Stroke (CVA)6.214013.81057Ballas (1982), Colella (2015), Ghunney (2023), Leveziel (2011), Moreira (2006)Acute pyelonephritis8.16695.7329Ballas (1982), Leveziel (2011) Note: This table presents the prevalence of acute complications in HbSS and HbSC genotypes in SCD. Percentages and numbers are shown, respectively. a VOC = vaso‐occlusive crisis—including ≥ 3 episodes per year. b Including patients with at least one ACS event. c Including men who have experienced one or more episodes of priapism. Prevalence of acute complications in HbSS and HbSC genotypes in SCD. Note: This table presents the prevalence of acute complications in HbSS and HbSC genotypes in SCD. Percentages and numbers are shown, respectively. VOC = vaso‐occlusive crisis—including ≥ 3 episodes per year. Including patients with at least one ACS event. Including men who have experienced one or more episodes of priapism. TABLE 3Prevalence of chronic complications in HbSS and HbSC genotypes in SCD.% of HbSS patients with eventTotal amount of HbSS patients (n)% of HbSC patients with eventTotal amount of HbSC patients (n)Studies usedOcularProliferative sickle retinopathy16.7317244.71948AIRyalat (2021), Condon (1980), Downes (2005), Fox (1990), Ghunney (2023), Leveziel (2011), Meurs (1990)Retinopathy a 21.890656.2505Ballas (1982), Beral (2019), Clarkson (1992), Colella (2015), Condon (1972), Leveziel (2011), Moreira (2006)With severe vision loss b 0.78198439Clarkson (1992), Leveziel (2011), Meurs (1990)Sickle cell macolopathy (SCM) c 52.3793657Beral (2019), Sahak (2020)Epiretinal membrane (ERM)2.62414.9252Clarkson (1992), Moriarty (1987)Iris atrophy0.83726.7358Acheson (1986), Clarson (1992), Meurs (1991)OtologicalHearing loss39.88958.153Crawford (1991), Jonavic (2006)PulmonaryPulmonary hypertension d 35.775058.2378Colella (2015), Klings (2008), Leveziel (2011)CardiovascularLeft‐sided heart disease e 23.67838391Guedeney (2018), Klings (2008), Leveziel (2011)Arterial hypertension f 4.66997.8699Ghunney (2023), Guedeney (2018)RenalNephropathy in general g 27.7144316.51031Beral (2019), Ephraim (2015), Ghunney (2023), Leveziel (2011)Renal papillary necrosis2266437.1654Ballas (1982), Ghunney (2023)Albuminuria h 38.3106625753Drawz (2016), Ephraim (2015), Ghunney (2023)Avascular necrosis (AVN)Osteonecrosis in general i 16.595722452Beral (2019), Colella (2015), Hill (1975), Leveziel (2011), Moreira (2006)Of the humeral head12.122814.8116David (1993), Ghunney (2023), Milner (1993)Of the femoral head j 38.966544.4661Lins (2021), Ghunney (2023)OtherSplenomegaly6.724233.765Ballas (1982), Bortolotti (2020), Olaniyi (2007)Hepatomegaly64.622624.752Ballas (1982), Olaniyi (2007)Cholelithiasis656035.930Ballas (1982), Bortolotti (2020)Leg ulcers15.88351.8765Ballas (1982), Beral (2019), Colella (2015), Ghunney (2023)Infections k 146945.6376Ballas (1982), Leveziel (2011)Osteomyelitis8.76934.3336Ballas (1982), Leveziel (2011)Priapism l 25.95885.4400Ballas (1982), Fowler (2018), Ghunney (2023), Leveziel (2011) Note: This table presents the prevalence of chronic complications in HbSS and HbSC genotypes in SCD. Percentages and numbers are shown, respectively. a Including retinopathy at Goldberg stage 3, when tis was specified. Also including arteriolar occlusions and retinitis proliferans. b Including retinopathy at the most advanced stage: Goldberg stage V. Retinal detachment often results into blindness. c SCM in ≥ 1 eye. d Defined as TRJ ≥ 2.5 m/s with a pulmonary arterial pressure ≥ 40 mmHg. e Defined as either left‐sided systolic/diastolic dysfunction, significant valvular disease, LV hypertrophy or cardiomyopathy. f Ghunney (2023) specified it as “systemic hypertension.” g Including chronic kidney disease, Ephraim (2015). h Including both microalbuminuria and macroalbuminuria. i Not specified in which bone the osteonecrosis was. j Including symptomatic AVN of at least 1 femoral head. k Including pneumonia‐, pyelonephritis‐, urinary tract‐ and en salmonellosis infections. l Including men who have experienced one or more episodes of priapism. Prevalence of chronic complications in HbSS and HbSC genotypes in SCD. Note: This table presents the prevalence of chronic complications in HbSS and HbSC genotypes in SCD. Percentages and numbers are shown, respectively. Including retinopathy at Goldberg stage 3, when tis was specified. Also including arteriolar occlusions and retinitis proliferans. Including retinopathy at the most advanced stage: Goldberg stage V. Retinal detachment often results into blindness. SCM in ≥ 1 eye. Defined as TRJ ≥ 2.5 m/s with a pulmonary arterial pressure ≥ 40 mmHg. Defined as either left‐sided systolic/diastolic dysfunction, significant valvular disease, LV hypertrophy or cardiomyopathy. Ghunney (2023) specified it as “systemic hypertension.” Including chronic kidney disease, Ephraim (2015). Including both microalbuminuria and macroalbuminuria. Not specified in which bone the osteonecrosis was. Including symptomatic AVN of at least 1 femoral head. Including pneumonia‐, pyelonephritis‐, urinary tract‐ and en salmonellosis infections. Including men who have experienced one or more episodes of priapism. Acute Complications Five acute key complications of sickle cell disease (SCD) were analyzed in HbSS and HbSC genotypes (Table 2). Painful sickle crises emerged as the most common acute complication across both genotypes, occurring in approximately 47% of HbSS patients and 29% of HbSC patients [9, 20, 21]. Despite their prevalence in both, these crises occur more frequently in the HbSS population, reflecting a higher burden in this genotype. Additional acute complications also occurred more frequently in HbSS patients compared to HbSC. Acute chest syndrome (ACS) was documented in 19% of HbSS patients and less than 10% of HbSC patients, suggesting a greater respiratory risk in HbSS [9, 21, 22, 23, 24, 25]. Priapism was nearly five times more prevalent in HbSS patients (26%) than in HbSC patients (less than 6%), highlighting a significant difference in this condition between genotypes [9, 20, 24, 26]. Stroke was observed in 6% of HbSS patients and less than 4% of HbSC patients, further suggesting a higher vascular complication risk in HbSS [9, 20, 23, 24, 25]. Finally, acute pyelonephritis occurred in 8% of HbSS patients compared to 6% of HbSC patients, underscoring the overall trend of a slightly increased susceptibility to acute complications in HbSS patients [20, 24]. Chronic Complications In total, 22 chronic complications in both HbSS and HbSC disease have been studied (Table 3). Ocular It was shown in seven studies that proliferative sickle retinopathy (PSR) occurred in 17% of HbSS patients and 45% of HbSC patients, indicating a higher prevalence in the HbSC group [9, 17, 24, 27, 28, 29, 30]. Additionally, overall retinopathy (Goldberg stage 3) was found in 22% of HbSS patients and 56% of HbSC patients, reflecting both conditions occurring twice as often in HbSC patients compared to HbSS patients [20, 21, 23, 31, 32]. Retinopathy at its most advanced stage (Goldberg stage 5), which is characterized by vision loss, was reported to be up to eight times more common in patients with HbSC disease than in those with HbSS disease. Severe vision loss was observed in 0.7% of patients with HbSS compared with 8% of HbSC patients [17, 24, 31]. According to two studies [21, 33], sickle cell maculopathy (SCM) was observed more frequently in HbSS than in HbSC, affecting 52% of HbSS patients compared to 36% of HbSC patients. The occurrence of epiretinal membranes (ERM) was documented in 3% of HbSS patients versus 5% of HbSC patients [31, 34] while iris atrophy was reported in 0.8% of HbSS patients and 7% of HbSC patients [18, 31, 35]. And finally, two papers studied the role of optical coherence tomography angiography and the importance of macular electrophysiological dysfunction in SCD, respectively [36, 37]. Fares et al. [36] published in their cross‐sectional study that HbSS genotype, abnormal coagulation, and hemolysis increase the risk of sickle cell maculopathy. It was noted that optical coherence tomography angiography improved early detection of microvascular changes before onset of macular thinning. And Beral et al. [37] reported on macular electrophysiological dysfunction in SCD. They confirmed that SCD maculopathy is equally frequent in HbSS and HbSC. Otological Hearing loss was more prevalent in HbSC patients, observed in 58% compared to 40% in HbSS patients, as reported in studies previously [38, 39]. The underlying mechanism in SCD is vaso‐occlusive ischemic injury of the cochlea and other auditory/vestibular structures [40]. Of note, the role of the cochlea is important as its limited vascular reserve is of crucial importance. This makes sensorineural hearing loss one of the most important otologic complications of SCD. This suggests a notable susceptibility to auditory impairment in HbSC patients. Pulmonary/Cardiovascular Pulmonary hypertension occurred more frequently in HbSC patients, with a prevalence of 58%, compared to 36% in HbSS patients, according to different studies [23, 24, 41]. These studies used echocardiography. In the study of Parent et al. [42], the prevalence of pulmonary hypertension as confirmed on right catheterization was 6%. The authors concluded that echocardiographic evaluation alone had a low positive predictive value for pulmonary hypertension. These findings highlight pulmonary hypertension as a more prominent complication in HbSC disease. Left‐sided heart disease was more common in HbSS, affecting 24% of patients compared to only 8% in HbSC, as shown earlier [19, 24, 41]. Arterial hypertension showed a slightly higher prevalence in HbSC patients (8%) versus HbSS (5%), as reported previously [9, 19]. Renal General nephropathy was more prevalent in HbSS, occurring in 28% of cases compared to 17% in HbSC [9, 21, 24, 43]. Renal Papillary Necrosis was more frequent in HbSC patients, affecting 37% compared to 22% in HbSS [9, 20]. Higher rates of albuminuria were found in HbSS patients (38%) than in HbSC (25%), based on studies in the past [9, 43, 44]. Avascular Necrosis (AVN) Osteonecrosis in general was observed more frequently in HbSC patients, with a prevalence of 22% compared to 17% in HbSS [21, 23, 24, 25, 45]. Osteonecrosis of the humeral head was also slightly more frequent in HbSC patients (15%) than in HbSS (12%) [9, 46, 47]. Femoral head osteonecrosis was more common in HbSC at 44% compared to 39% in HbSS [9, 48]. Other Complications Splenomegaly was more commonly observed in HbSC patients (34%) than in those with HbSS (7%) [20, 49, 50]. Conversely, a higher incidence of hepatomegaly was noted in HbSS patients in two‐third of cases, compared to a quarter of HbSC patients [20, 50]. Additionally, cholelithiasis was more prevalent in HbSS patients (65%) than in HbSC patients (36%) [20, 49]. Leg ulcers were more frequently reported in HbSS patients (16%) than in HbSC (2%) [9, 20, 21, 23]. Infections were also more common in HbSS patients, with a prevalence of 14% compared to 6% in HbSC [20, 24]. Osteomyelitis was observed in 9% of HbSS patients and 4% of HbSC patients [20, 24]. Discussion The aim of this systematic review was to give an update and overview of the acute and chronic complications associated with sickle cell disease (SCD). This chronic disease has a different disease presentation per SCD genotype and is considered devastating in low‐income and middle‐income countries (LMICs) [51]. With this overview, we shed light on the differences between HbSS and HbSC in terms of complications, underscoring the importance of understanding these differences to develop more effective and individualized treatment strategies. As it is necessary to improve survival rates, reduce hospitalizations, and enhance quality of life for millions of patients worldwide. To our knowledge, this is the only systematic review to date that provides an overview of both acute and chronic complications in sickle cell disease, including 10 articles published in 2015 or later. In this way, we offer a unique integrated perspective on the full spectrum of health challenges faced by individuals with SCD. Existing Literature on Acute and Chronic SCD Complications Current literature on HbSS and HbSC shows that acute complications, most notably vaso‐occlusive crises (VOCs), are frequently reported in both genotypes, leading to high rates of emergency care visits and hospitalizations [52]. While HbSS is typically associated with more frequent and severe VOCs, HbSC patients tend to experience a milder course, although VOCs still significantly impact their health [53]. Acute chest syndrome is another complication, particularly common in HbSS, contributing to frequent hospitalizations [54, 55]. Chronic complications in SCD affect both HbSS and HbSC populations, though their incidence and severity can differ. For example, HbSC patients experience higher rates and more severe forms of sickle cell retinopathy compared to other types of SCD, including HbSS [56]. The exact pathophysiology remains unclear, but may be related to the higher blood viscosity observed in HbSC patients compared to those with HbSS [57]. These chronic complications occur in both genotypes, often exacerbated by cumulative vascular injury and inflammatory processes due to the sickling red blood cells. This contributes to progressive morbidity and premature mortality in these populations [58]. The literature highlights the need for genotype‐specific treatment strategies due to these differences in acute and chronic complications. While treatments like hydroxycarbamide [59] and (pre‐operative) blood transfusions [60] have shown promise in reducing complications, a definitive cure remains elusive for most patients. Current management strategies focus on reducing the frequency and severity of acute complications and attempting to slow the progression of chronic organ damage. Given the distinct and shared impacts of HbSS and HbSC, a more comprehensive understanding of these differences is critical to developing improved, tailored therapeutic approaches to better address the needs of individuals with each genotype. Study Strengths and Limitations This review has several strengths, including its comprehensive approach to examining the occurrence of complications in both HbSS and HbSC genotypes. By including only studies that investigated both genotypes, we were able to directly compare the two populations, offering a clearer understanding of the similarities and differences in complications between HbSS and HbSC. However, this also represents a potential limitation, as we excluded studies that focused solely on HbSS or HbSC, which may have resulted in the loss of valuable data regarding the specific complications in these genotypes. Another limitation is that we did not use it as an additional inclusion or exclusion criterion, besides the criteria which was mentioned in the methods section. This could imply that studies with varying levels of methodological rigor were still included. This could introduce selection bias and/or information bias or affect the generalizability of our findings. However, most of the studies included in our systematic review were assessed as being of moderate to high methodological quality, which supports the reliability of our findings. Furthermore, we excluded studies involving children, focusing on patients with an age greater than 20 years to minimize the influence of pediatric data on our results. This is due to differences in disease presentation, metabolism, and pathophysiology between children and adults. Since age groups were often defined with a cutoff at 20 years, we chose to adopt 20 years as our cutoff point as well. While this exclusion criterion ensured a more homogenous adult population, it also limited the breadth of the studies considered, potentially underrepresenting complications that might be more prevalent or present differently in younger populations. We emphasize the need for a separate future review, as pediatric complications may differ and deserve special attention. Despite these limitations, the strengths of our study lie in its focus on adult populations, the direct comparison of HbSS and HbSC, and its thorough exploration of acute and chronic complications across these genotypes. Future Perspectives Future research in sickle cell disease (SCD) should prioritize novel therapies that address both acute crises and chronic complications, aiming to alleviate the lifelong burden of the disease. However, not all new therapies may be accessible or practical in LMIC's. Consider limited access to medications, lack of resources for comprehensive monitoring of all chronic complications and cultural or economic barriers to SCD management. This highlights the need to consider future perspectives for LMIC's and high‐income countries separately. Advanced therapies such as CRISPR‐Cas9 [61], innovative anti‐sickling agents, such as Cajanus cajan extracts [62] and gum Arabic [63], immunotherapies [64], and hematopoietic stem cell transplantation (HSCT) [65] offer promising solutions to reduce complications, prevent organ damage and address the root causes of sickle cell disease (SCD). In high‐income countries, these approaches, combined with precision medicine, can enable personalized treatments tailored to genetic and environmental factors. In LMIC, the focus should shift towards affordable, practical interventions and community‐based care models to address disparities in healthcare access. In parallel, early preventive strategies such as neonatal screening combined with prophylaxis (penicillin, vaccination) are cost‐effective in most SSA countries; it would cost an average of ~$190 per DALY saved [66]. Given the high annual birth rate in SSA, substantial benefits can be achieved through targeting one of the most vulnerable and yet most at‐risk populations. We suggest clinical trials which include HbSC subjects, as it is essential to assess the safety and likewise efficacy issues of treatment. By integrating precision medicine globally, these advancements can improve outcomes and quality of life for individuals with SCD. Conclusions Our analysis of 31 studies highlights key differences in complications between HbSS and HbSC genotypes in sickle cell disease (SCD). Vaso‐occlusive crises (VOCs) remain the most common acute complication in both genotypes. HbSS patients experience more frequent VOCs, while HbSC patients generally have a milder clinical course when it comes to acute complications. However, HbSC patients still face a significant health burden. Chronic complications, particularly in the ocular and pulmonary systems, are more prevalent in HbSC patients. However, as acute complications are more common in HbSS and chronic complications more common in HbSC, both genotypes face progressive organ damage due to recurrent ischemic injury and inflammation. The interaction between acute and chronic complications underscores the complexity of SCD and the need for integrated treatment strategies that address both acute and chronic complications. Our findings highlight the importance of adjusting treatment to the specific complications and risks associated with each genotype to improve outcomes and quality of life for both HbSS and HbSC patients. Author Contributions M.M., K.V., and W.H.T. designed, analyzed, and interpreted the data. J.W.S. was responsible for the extended PubMed search. M.M., K.V., and J.W.S. did the analysis of all references. W.H.T. supervised this research; all authors were responsible for the manuscript preparation; and all authors revised this review article critically for important intellectual content and approved the final version to be published. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Data S1: The risk of bias (ROB) assessments for the selected studies are also summarized in this section.